

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation

Manufacturer or supplier's details

Company : MSD

Address : 199 Wenhai North Road
HEDA, Hangzhou - Zhejiang Province - CHINA 310018

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

| | |
|------------|---------------------|
| Appearance | : powder |
| Colour | : white |
| Odour | : No data available |

Harmful to aquatic life. Very toxic to aquatic life with long lasting effects.

GHS Classification

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 1

GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H402 Harmful to aquatic life.
H410 Very toxic to aquatic life with long lasting effects.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Precautionary statements : **Prevention:**
P273 Avoid release to the environment.

Response:
P391 Collect spillage.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

Not classified based on available information.

Environmental hazards

Harmful to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|--------------------|--------------|-----------------------|
| Sodium chloride | 7647-14-5 | ≥ 1 -< 10 |
| Cellulose | 9004-34-6 | ≥ 1 -< 10 |
| Grazoprevir | 1350462-55-3 | ≥ 2.5 -< 10 |
| Elbasvir | 1370468-36-2 | ≥ 2.5 -< 10 |
| Magnesium stearate | 557-04-0 | ≥ 1 -< 10 |
| Titanium dioxide | 13463-67-7 | ≥ 0.1 -< 1 |

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

| | |
|---|---|
| If swallowed | : If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| Notes to physician | : Treat symptomatically and supportively. |

5. FIREFIGHTING MEASURES

| | |
|---|---|
| Suitable extinguishing media | : Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical |
| Unsuitable extinguishing media | : None known. |
| Specific hazards during fire-fighting | : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : Carbon oxides Metal oxides Chlorine compounds Nitrogen oxides (NO _x) |
| Specific extinguishing methods | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area. |
| Special protective equipment for firefighters | : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment. |

6. ACCIDENTAL RELEASE MEASURES

| | |
|---|--|
| Personal precautions, protective equipment and emergency procedures | : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 8.1 | 2025/08/07 | 76207-00031 | 2025/04/14 |
| | | | Date of first issue: 2015/03/17 |

cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--|--------------|-------------------------------------|--|----------|
| Cellulose | 9004-34-6 | PC-TWA | 10 mg/m ³ | CN OEL |
| | | TWA | 10 mg/m ³ | ACGIH |
| Grazoprevir | 1350462-55-3 | TWA | 260 µg/m ³ (OEB 2) | Internal |
| Elbasvir | 1370468-36-2 | TWA | 150 µg/m ³ (OEB 2) | Internal |
| Magnesium stearate | 557-04-0 | TWA (Inhalable particulate matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |
| Titanium dioxide | 13463-67-7 | PC-TWA (Total dust) | 8 mg/m ³ | CN OEL |
| Further information: G2B - Possibly carcinogenic to humans | | | | |

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hand protection : Chemical-resistant gloves

Material : Chemical-resistant gloves

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

| | |
|--|---|
| Appearance | : powder |
| Colour | : white |
| Odour | : No data available |
| Odour Threshold | : No data available |
| pH | : No data available |
| Melting point/freezing point | : No data available |
| Initial boiling point and boiling range | : No data available |
| Flash point | : Not applicable |
| Evaporation rate | : Not applicable |
| Flammability (solid, gas) | : May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : No data available |
| Upper explosion limit / Upper flammability limit | : No data available |
| Lower explosion limit / Lower flammability limit | : No data available |
| Vapour pressure | : Not applicable |
| Relative vapour density | : Not applicable |
| Relative density | : No data available |
| Density | : No data available |
| Solubility(ies) | |
| Water solubility | : No data available |
| Partition coefficient: n-octanol/water | : Not applicable |
| Auto-ignition temperature | : No data available |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics
Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Sodium chloride:

Acute oral toxicity : LD50 (Rat): 3,550 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 42 mg/l
Exposure time: 1 h
Test atmosphere: dust/mist

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Grazoprevir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Elbasvir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 1,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Sodium chloride:

Species : Rabbit
Result : No skin irritation

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Grazoprevir:

Result : No skin irritation

Elbasvir:

Species : reconstructed human epidermis (RhE)

Result : No skin irritation

Magnesium stearate:

Species : Rabbit

Result : No skin irritation

Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Sodium chloride:

Species : Rabbit

Result : No eye irritation

Grazoprevir:

Species : Bovine cornea

Result : No eye irritation

Elbasvir:

Species : Bovine cornea

Result : No eye irritation

Magnesium stearate:

Species : Rabbit

Result : No eye irritation

Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rabbit

Result : No eye irritation

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Sodium chloride:

| | |
|-----------------|---------------------------------|
| Test Type | : Local lymph node assay (LLNA) |
| Exposure routes | : Skin contact |
| Species | : Mouse |
| Result | : negative |

Grazoprevir:

| | |
|-----------------|---------------------------------|
| Test Type | : Local lymph node assay (LLNA) |
| Exposure routes | : Dermal |
| Result | : Not a skin sensitizer. |

Elbasvir:

| | |
|-----------------|---------------------------------|
| Test Type | : Local lymph node assay (LLNA) |
| Exposure routes | : Dermal |
| Species | : Mouse |
| Result | : negative |

Magnesium stearate:

| | |
|-----------------|--|
| Test Type | : Maximisation Test |
| Exposure routes | : Skin contact |
| Species | : Guinea pig |
| Method | : OECD Test Guideline 406 |
| Result | : negative |
| Remarks | : Based on data from similar materials |

Titanium dioxide:

| | |
|-----------------|---------------------------------|
| Test Type | : Local lymph node assay (LLNA) |
| Exposure routes | : Skin contact |
| Species | : Mouse |
| Result | : negative |

Germ cell mutagenicity

Not classified based on available information.

Components:

Sodium chloride:

| | |
|-----------------------|---|
| Genotoxicity in vitro | : Test Type: In vitro mammalian cell gene mutation test |
| | Result: positive |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Saccharomyces cerevisiae, gene mutation assay (in vitro)
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Test Type: Chromosome aberration test in vitro
Result: positive

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Intraperitoneal injection
Result: positive

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Elbasvir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Rat
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Not classified based on available information.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Components:

Sodium chloride:

| | |
|-------------------|-------------|
| Species | : Rat |
| Application Route | : Ingestion |
| Exposure time | : 2 Years |
| Result | : negative |

Cellulose:

| | |
|-------------------|-------------|
| Species | : Rat |
| Application Route | : Ingestion |
| Exposure time | : 72 weeks |
| Result | : negative |

Titanium dioxide:

| | |
|-------------------|--|
| Species | : Rat |
| Application Route | : inhalation (dust/mist/fume) |
| Exposure time | : 2 Years |
| Method | : OECD Test Guideline 453 |
| Result | : positive |
| Remarks | : The mechanism or mode of action may not be relevant in humans. |

| | |
|------------------------------|---|
| Carcinogenicity - Assessment | : Limited evidence of carcinogenicity in inhalation studies with animals. |
|------------------------------|---|

Reproductive toxicity

Not classified based on available information.

Components:

Cellulose:

| | |
|----------------------|---|
| Effects on fertility | : Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative |
|----------------------|---|

| | |
|-------------------------------|--|
| Effects on foetal development | : Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative |
|-------------------------------|--|

Grazoprevir:

| | |
|----------------------|--|
| Effects on fertility | : Test Type: Fertility Species: Rat Application Route: Oral Fertility: NOAEL: 400 mg/kg body weight Result: negative |
|----------------------|--|

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

| | | |
|-------------------------------|---|--|
| | | Test Type: Multi-generation study Species: Rat Application Route: Oral Fertility: NOAEL: 400 mg/kg body weight Result: No effects on fertility, No effects on foetal development |
| Effects on foetal development | : | Test Type: Embryo-foetal development Species: Rat Application Route: Oral Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight Result: No effects on foetal development Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight Result: No effects on foetal development Test Type: Embryo-foetal development Species: Rabbit Application Route: Intravenous Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight Result: No effects on foetal development |
| Elbasvir: | | |
| Effects on fertility | : | Test Type: Fertility/early embryonic development Species: Rat, male and female Application Route: Oral Fertility: NOAEL: 1,000 mg/kg body weight Result: No effects on fertility |
| Effects on foetal development | : | Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Result: No effects on early embryonic development Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Result: No effects on early embryonic development |
| Magnesium stearate: | | |
| Effects on fertility | : | Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test Species: Rat Application Route: Ingestion Method: OECD Test Guideline 422 Result: negative |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Grazoprevir:

Target Organs : Liver, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Sodium chloride:

Species : Rat
LOAEL : 2,533 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

Cellulose:

Species : Rat
NOAEL : $\geq 9,000$ mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Grazoprevir:

Species : Rat
NOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 30 Days
Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 180 Days
Remarks : No significant adverse effects were reported

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Species : Dog
NOAEL : 15 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 270 Days
Target Organs : Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species : Mouse
NOAEL : 200 mg/kg
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 90 Days
Target Organs : Liver, Kidney, Blood

Species : Dog
NOAEL : 20 mg/kg
LOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 30 Days
Target Organs : Blood, Testis

Species : Monkey
NOAEL : 10 mg/kg
Exposure time : 8 Days
Remarks : No significant adverse effects were reported

Elbasvir:

Species : Rat
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 180 d
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 270 d
Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Titanium dioxide:

Species : Rat

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

| | | |
|-------------------|---|-----------------------------|
| NOAEL | : | 24,000 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 28 Days |
| Species | : | Rat |
| NOAEL | : | 10 mg/m3 |
| Application Route | : | inhalation (dust/mist/fume) |
| Exposure time | : | 2 yr |

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Grazoprevir:

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

Elbasvir:

Ingestion : Symptoms: Headache, Abdominal pain, constipation, Nausea, Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irritation, rhinitis, Drowsiness, nasal congestion

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Sodium chloride:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 4,136 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50: > 2,000 mg/l
Exposure time: 96 h

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 252 mg/l
Exposure time: 33 d

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia pulex (Water flea)): 314 mg/l
Exposure time: 21 d

Toxicity to microorganisms : EC10: > 1,000 mg/l

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Remarks: Based on data from similar materials

Grazoprevir:

- Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility
- LC50 (Americamysis): 8.9 mg/l
Exposure time: 96 h
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility
- NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 5 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
- NOEC: 1.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Elbasvir:

- Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l
Exposure time: 96 h

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 8.1 | 2025/08/07 | 76207-00031 | 2025/04/14 |
| | | | Date of first issue: 2015/03/17 |

| | | |
|--|---|---|
| | | Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility |
| | | LC50 (Menidia beryllina (Silverside)): > 10 mg/l Exposure time: 96 h Remarks: No toxicity at the limit of solubility |
| Toxicity to daphnia and other aquatic invertebrates | : | EC50 (Daphnia magna (Water flea)): > 10 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: No toxicity at the limit of solubility |
| | | LC50 (Americamysis): 7.7 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility |
| Toxicity to algae/aquatic plants | : | EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility |
| | | NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility |
| Toxicity to fish (Chronic toxicity) | : | NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : | NOEC (Daphnia magna (Water flea)): 0.84 mg/l Exposure time: 21 d Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility |
| M-Factor (Chronic aquatic toxicity) | : | 10 |
| Toxicity to microorganisms | : | EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |
| | | NOEC: 271.9 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 |
| Magnesium stearate: | | |
| Toxicity to fish | : | LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l |

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: |
| 8.1 | 2025/08/07 | 76207-00031 | 2025/04/14 |
| | | | Date of first issue: 2015/03/17 |

Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (*Daphnia magna* (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (*Pseudokirchneriella subcapitata* (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (*Pseudokirchneriella subcapitata* (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (*Pseudomonas putida*): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Titanium dioxide:

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (*Skeletonema costatum* (marine diatom)): > 10,000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Biodegradability : Result: Readily biodegradable.

Grazoprevir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 66 %
Exposure time: 28 d

Elbasvir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 37 %
Exposure time: 28 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Grazoprevir:

Bioaccumulation : Species: *Lepomis macrochirus* (Bluegill sunfish)
Bioconcentration factor (BCF): 7.62

Partition coefficient: n-octanol/water : log Pow: 3.72

Elbasvir:

Bioaccumulation : Species: *Lepomis macrochirus* (Bluegill sunfish)
Bioconcentration factor (BCF): 82
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 6.54

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Grazoprevir:

Distribution among environmental compartments : log Koc: 4.01

Elbasvir:

Distribution among environmental compartments : log Koc: 5.24

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

| | | |
|------------------------|---|---|
| Waste from residues | : | Do not dispose of waste into sewer. Dispose of in accordance with local regulations. |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

| | | |
|---------------------------|---|--|
| UN number | : | UN 3077 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| Environmentally hazardous | : | yes |

IATA-DGR

| | | |
|--|---|--|
| UN/ID No. | : | UN 3077 |
| Proper shipping name | : | Environmentally hazardous substance, solid, n.o.s. (Elbasvir) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | Miscellaneous |
| Packing instruction (cargo aircraft) | : | 956 |
| Packing instruction (passenger aircraft) | : | 956 |
| Environmentally hazardous | : | yes |

IMDG-Code

| | | |
|----------------------|---|--|
| UN number | : | UN 3077 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| EmS Code | : | F-A, S-F |
| Marine pollutant | : | yes |

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

National Regulations

GB 6944/12268

| | | |
|----------------------|---|---|
| UN number | : | UN 3077 |
| Proper shipping name | : | ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir) |
| Class | : | 9 |
| Packing group | : | III |
| Labels | : | 9 |
| Marine pollutant | : | no |

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

| | | |
|----------------------------------|---|---|
| Catalogue of Hazardous Chemicals | : | This product is not listed in the catalogue of hazardous chemicals, but it meets the definition of hazardous chemicals and its principles of determination. |
|----------------------------------|---|---|

| | | |
|---|---|------------|
| Identification of Major Hazard Installations for Hazardous Chemicals (GB 18218) | : | Not listed |
|---|---|------------|

| | | |
|--|---|------------|
| Hazardous Chemicals for Priority Management under SAWS | : | Not listed |
|--|---|------------|

| | | |
|---|---|------------|
| Catalogue of Specially Controlled Hazardous Chemicals | : | Not listed |
|---|---|------------|

| | | |
|------------------------------|---|------------|
| List of Explosive Precursors | : | Not listed |
|------------------------------|---|------------|

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

| | | |
|-------------------------------------|---|------------|
| Catalogue of Highly Toxic Chemicals | : | Not listed |
|-------------------------------------|---|------------|

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

| | | |
|---|---|------------|
| China Severely Restricted Toxic Chemicals for Import and Export | : | Not listed |
|---|---|------------|

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import and Export : Not listed

List of Controlled Ozone Depleting Substances : Not listed

Environmental Protection Law

List of Priority Controlled Chemicals : Not listed

List of Key Controlled New Pollutants : Not listed

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2025/08/07

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CN OEL : Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.

ACGIH / TWA : 8-hour, time-weighted average

CN OEL / PC-TWA : Permissible concentration - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with

SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



Grazoprevir / Elbasvir Formulation

| | | | |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 2025/04/14 |
| 8.1 | 2025/08/07 | 76207-00031 | Date of first issue: 2015/03/17 |

x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN